BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial

Cancer Letters

Volumn 247, Issue 2, 2007, Pages 259-265

  Kote Jarai, Zsofia ^a   Powles, Trevor J ^b   Mitchell, Gillian ^a   Tidy, Alwynne ^b   Ashley, Sue ^b   Easton, Douglas ^c   Assersohn, Laura ^b   Sodha, Nayanta ^a   Salter, Janine ^b   Gusterson, Barry ^d   Dowsett, Mitch ^b   Eeles, Rosalind ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast cancer; Chemoprevention; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PEDIGREE ANALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 33846917315     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.05.003     Document Type: Article

References (21)

1. Bergh J. Breast cancer prevention: is the risk-benefit ratio in favour of tamoxifen?. Lancet 362 (2003) 183-184
2. Fisher B., Costantino J., Wickerham D., Redmond C., Kavanah M., Cronin W., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., and Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. NCI 90 (1998) 1371-1388
3. IBIS Investigators, First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 360 (2002) 817-824.
4. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy V., Viggers J., and Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (1998) 98-101
5. Cuzick J., and IBIS. A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposal for future trials. Ann. NY Acad. Sci. 949 (2001) 123-133
6. Gail M., Brinton L., Byar D., Corle D., Green S., and Schairer D. Projecting individualised probabilities of developing breast cancer for white females who are examined annually. J. Natl. Cancer Inst. 81 (1989) 1879-1886
7. Lakhani S., Jacquemier J., Sloane J., Gusterson B., Anderson T., and van de Vijver M. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90 (1998) 1138-1145
8. Claus E., Risch N., and Thompson W. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet. 48 (1991) 232-242
9. http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic.
10. Available at .
11. Gayther S., Harrington P., Russell P., Kharkevich G., and Garkavtseva R. Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am. J. Hum. Genet. 58 (1996) 451-456
12. Saccani-Jotti G., Johnston S., Salter J., Detre S., and Dowsett M. Comparison of a new histochemical assay for oestrogen receptor in paraffin embedded breast carcinomas with quantitative immunoassay. J. Clin. Pathol. 47 (1994) 900-905
13. Allan S.M., Dean C., Fernando I., Eccles S., Styles J., McCready V.R., Baum M., and Sacks N. Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br. J. Cancer 67 (1993) 706-712
14. Newby J., A'Hern R., Leek R., Smith I., Harris A., and Dowsett M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br. J. Cancer 71 (1995) 1237-1242
15. Bloom H.J.G., Richardson W.W., and Harries E.J. Natural history of untreated breast cancer (1805-1933): comparison of untreated and treated cases according to histological grade of malignancy. Br. Med. J. MJ 2 (1962) 213-221
16. Chlebowski R., Collyar D., Somerfield M., and Pfister D. American Society of Clinical Oncology: Technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J. Clin. Oncol. 17 (1999) 1939-1955
17. King M.C., Wieand S., Hale K., Lee M., Walsh T., Owens K., Tait J., Ford L., Dunn B.K., Costantino J., Wickerham L., Wolmark N., and Fisher B. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286 (2001) 2251-2256
18. Gail M., and Benichou J. Validation studies on a model for breast cancer risk. J. Natl. Cancer Inst. 86 (1994) 573-575
19. Antoniou A.C., Pharoah P.P., Smith P., and Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br. J. Cancer 91 (2004) 1580-1590
20. Evans D.G.R., Eccles D.M., Rahman N., Young K., Bulman M., Amir E., Shenton A., Howell A., and Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J. Med. Genet. 41 (2004) 474-480
21. Narod S., Brunet J.S., Ghadirian P., Robson M., Heimdal K., Neuhausen S., Stoppa-Lyonnet D., Lerman C., Pasini B., de los Rios P., Weber B., and Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet 356 (2000) 1876-1881